GLP-1 Drugs Enable Safe Insulin Reduction in Advanced Type 2 Diabetes | Research

The takeaway

GLP-1 receptor agonists and SGLT2 inhibitors can safely reduce or eliminate insulin requirements in advanced T2D, reducing hypoglycemia and weight gain while maintaining glycemic control.

Insulin freedom possible
GLP-1 drugs enable some advanced T2D patients to completely discontinue insulin while maintaining blood sugar control

What the researchers found

GLP-1 RAs enable safe insulin dose reduction or complete deinsulinization in advanced T2D, with maintained glycemic control, reduced hypoglycemia, and weight loss.

Why it matters

Millions of T2D patients are on insulin they may no longer need. Safe deinsulinization with GLP-1 drugs can eliminate the burden and risks of unnecessary insulin therapy.

How the study worked

Evidence-based review of strategies for insulin reduction and discontinuation using GLP-1 RAs and SGLT2i in advanced T2D.

What this study cannot tell us

Not all patients can discontinue insulin. Careful monitoring required during tapering. Some patients need insulin for beta-cell failure regardless of GLP-1 therapy.

How to read the evidence

Evidence-based review of clinical studies and guidelines for insulin reduction strategies.

When this study was published

Published in 2025.

The bigger picture

The shift from mandatory insulin to optional insulin in T2D represents a paradigm change enabled by GLP-1 peptide drugs.

Questions still open

Which patients are best candidates for insulin discontinuation?
What is the optimal tapering schedule?
Should new-onset T2D patients skip insulin entirely and start with GLP-1 drugs?

Common questions

Can GLP-1 drugs replace insulin for type 2 diabetes?

For many patients, yes. GLP-1 drugs can maintain blood sugar control while allowing insulin to be reduced or even stopped entirely, eliminating the weight gain and hypoglycemia that insulin causes.

Is it safe to stop insulin?

It must be done carefully with medical supervision. Not all patients can stop insulin, but for those who can, the benefits are significant: less weight gain, fewer dangerous low blood sugar episodes, and simpler treatment.

Read the original research

Deinsulinisation in type 2 Diabetes: Evidence-based strategies for safe treatment simplification "Approaches to reducing insulin in type 2 diabetes".

Diabetes research and clinical practice, 231, 113056

View on PubMed ↗Publisher’s paper ↗

Citation

Giorda, Carlo B; Anelli, Valentina; Goglia, Umberto; Riu, Stefano De; Russo, Giuseppina; Gallo, Marco; Cosmo, Salvatore De; Corigliano, Gerardo; Modestino, Michele Roberto. (2026). Deinsulinisation in type 2 Diabetes: Evidence-based strategies for safe treatment simplification "Approaches to reducing insulin in type 2 diabetes".. Diabetes research and clinical practice, 231, 113056. https://doi.org/10.1016/j.diabres.2025.113056